With the election of a new Congress, President, and agency leadership, there are questions about the trajectory of policies and guidelines and what will change for the biotech industry. As new priorities emerge, understanding the landscape and leadership is top of mind. This session will look to offer an inside the Beltway perspective on the year ahead in Washington and allow for a discussion with company leaders, policy experts, and investors to highlight priorities moving forward.​